Focused on research solutions that save you time and money while providing the data you need to move your bright ideas into practice.
490 BioTech serves the academic, commercial, industrial, and government research community by providing high quality bioluminescent cell lines that don’t require external luciferin treatments to function.
Our patented genetic architecture allows our cell lines to produce their own luciferin internally, allowing for continuous light production throughout the life of your culture.
490 BioTech’s core technology was developed and validated through years of academic research. We invite you to review our original peer-reviewed literature to learn more about our technology and how 490 BioTech’s cell lines can help you.
Meet the Founders
Dan Close, Gary Sayler, Steven Ripp, and Stacey Patterson founded 490 BioTech in 2011 following our initial demonstration of autobioluminescence from a human cell. Dan, Gary, and Steven, who together have over 60 years of specialized bioluminescent research and development experience, continue to harness the power of autobioluminescence to provide you with simple solutions for improving bioluminescent assays. As 490 BioTech has grown we have never lost sight of our mission to provide you with the tools you need to change the world.
Dr. Close provided the definitive proof-of-concept studies demonstrating the in vitro and in vivo emission of substrate-free bioluminescence from human cell lines. He leads 490’s R&D operations and oversees all scientific work.
Dr. Sayler pioneered the application of autobioluminescence as a sensor element and has published over 100 bioluminescence-related manuscripts. His expertise helps guide our product design.
Dr. Ripp has over 18 years experience in the administration of bioluminescence-based projects designed to solve health, environmental, and societal problems. He is responsible for the management of 490’s project portfolio.
Want to work with us?
We are looking for talented and passionate individuals to join our lab. Send us your information and we will contact you about open positions.
Our distributors serve areas around the globe throughout North America, Europe, and Asia.
Autobioluminescence outperforms endpoint assays. NIH/NCATS validates 490 BioTech’s HEK293 cell line as a high-throughput drug discovery tool.
Making waves in Biotech. 490 BioTech has been recognized as one of the top 5 Highly Promising Companies of 2018 by the Pepperdine Graziadio school of business.
Easier for technicians and less painful for subjects. NC3Rs recognizes autobioluminescence as a preferred method for improving animal welfare by removing the need for repeated luciferin injections.
Putting innovation to work. The introduction of autobioluminescent technology to the marketplace in 2013 was recognized as one of the top 10 most innovative new products of the year.